Skip to main content
. 2016 Mar 1;6:22419. doi: 10.1038/srep22419

Figure 1. Antiproliferative effects of 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al (TCD) in breast cancer cells, normal human breast epithelial cells, and primary bone marrow cells.

Figure 1

(A) The chemical structure of TCD. (B) Dose-dependent suppressive effects of TCD on the viability of MCF-7 and MDA-MB-231 breast cancer cells. Cells were treated with TCD at indicated concentrations in 5% fetal bovine serum (FBS)-supplemented DMEM/F12 medium for 24, 48, and 72 h, and cell viability was determined by MTT assays. Points, mean; bars, S.D. (n = 6). *P < 0.05; **P < 0.01. (C) Non-tumorgenic human breast epithelial cells (H184B5F5/M10) were treated with TCD for 24 h, and cell viability was determined by MTT assays. Points, mean; bars, S.D. (n = 6). (D) Normal bone marrow nuclear cells were incubated with TCD for 24 h. The cell viability was assessed using flow cytometry with annexin V-FITC and PI staining (n = 3).